VEGFA and thyroid tumor: Three main pharmacological classes can be identified, including tyrosine kinase inhibitors (TKIs), an essential therapeutic option especially in renal cell carcinoma and thyroid neoplasms, monoclonal antibodies (mAbs) such as bevacizumab in metastatic colorectal carcinoma, and VEGF soluble decoy receptor capturing free VEGF such as the fusion protein aflibercept [1].